Covers techniques for sequencing hybridomas, from cell line maintenance to antibody gene analysis.
Hybridoma technology, developed by Köhler and Milstein in 1975, introduced a method for the generation of monoclonal antibodies (mAbs) through the fusion of antigen-specific B lymphocytes with immortal myeloma cells. This approach enabled the long-term culture of hybrid cells—termed hybridomas—that produce highly specific antibodies targeting a single epitope.
Discover how hybridoma sequencing prevents cell line loss, ensures accurate antibody sequences, and enables recombinant expression for consistent, scalable antibody production.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
